PPT-SOF/VEL/VOX

400100100 mg QD N 501 N 440 W8 SOFVEL 400100 mg QD gt 18 years Chronic HCV infection Genotype 1 2 3 4 5 or 6 Treatmentnaïve or IFNexperienced Compensated cirrhosis allowed . of Social Psychology Director, J6/CIO . United States Special Operations Command. SOF C4. “One Force, . One Environment”. UNCLASSIFIED. UNCLASSIFIED. 8,463. DEPLOYED. 80. LOCATIONS. 24/7. 64,000. . SOF. Unified Commands. Versatile . Efficient. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. > . 18 years. HCV infection. G. enotype 1 or 4. Failure to a prior therapy with . SOF ± RBV + (SMV or DCV or LDV) . with documented presence of . NS5A or NS3 RASs at failure . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . W24. SOF/VEL. >. 18 years. Chronic HCV infection. Genotype 1 to 6. Naïve or treatment-experienced. No prior treatment with . NS5A or NS5B inhibitor. Child-Pugh B cirrhosis **. No . hepatocellular. is: Db.. Jesuh. . khuarhar. . vel. cu,. Ka . sual. . nakin. . ngan. . deuh. ,. Holh. in . zeiti’n. . kan. . phuan. . lai. ,. Khoika’h. ka . thang`hat. . lai. ,. Ka . thilrit. a ka . Visit us at vox.co.za CONCLUSIONThis will result in a ‘new’ normal inuenced by the learnings gained from this period of remote working. Companies will likely have to introduce a more &# NEVO+1200 M DATA SHEET _______________________________________________________________________________________________ DOC - DTS - 004 - 03, NEVO+1200M Medical Datasheet Vox Power Limited | Unit 2, Re ≥ 18 years. Chronic HCV infection. Genotype 1 or 4. HCV RNA > 10 000 IU/ml. Treatment-naïve or pre-treated. w. ith PEG-IFN ± RBV. Cirrhosis (> 14.5 . kPa. on . FibroScan. ). Portal hypertension or liver .